CNS Disorders  >>  MK0249  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK0249 / Merck (MSD)
NCT00475735: A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)

Completed
2a
72
US
MK0249, Concerta (methylphenidate), CONCERTA®, Placebo
Merck Sharp & Dohme LLC
Attention-Deficit/Hyperactivity Disorder (ADHD)
04/08
04/08
NCT00506077: MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Completed
2a
55
RoW
MK0249, Comparator: Placebo (unspecified)
Merck Sharp & Dohme LLC
Paranoid Schizophrenia
10/08
10/08
NCT00420420: MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Completed
2
144
US
MK0249, Comparator: Placebo (unspecified)
Merck Sharp & Dohme LLC
Alzheimer's Disease
08/08
08/08

Download Options